Merck To Present Final Stage Data On Investigational Medicines Ertugliflozin and MK-1293

Merck & Co., Inc.

disclosed that it would present final stage data on its Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association. According to the company, researchers would present data and over 20 scientific data presentations were expected to be made in New Orleans between June 10 and 14. Merck said that the new investigational clinical trial data to be presented included the first Phase 3 results for ertugliflozin, an oral SGLT2 inhibitor in development with Pfizer for patients with type 2 diabetes, and for MK-1293. Also included in the list was Merck's follow-on biologic insulin glargine candidate being evaluated for patients with type 1 and type 2 diabetes. The pharmaceutical firm said that more analyses would be presented from the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of JANUVIA. Merck's VP for late stage development, diabetes and endocrinology, commented, "At Merck, we have a long-term commitment to diabetes research and advancing the care of people living with diabetes around the world. We look forward to presenting new clinical trial data and results of several studies from real-world settings at this year's American Diabetes Association Scientific Sessions." Shares of the company traded 0.11% down on Thursday.